Skip to main content Skip to section navigation Skip to footer
Inhibikase Therapeutics, Inc.
  • Home
  • About
    • Management Team
    • Board of Directors
  • Pipeline
    • Overview
    • IkT-001 for PAH
  • News
    • Press Releases
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Contact

Press Releases

News

News

  • Press Releases
Oct 19, 2021 8:05am EDT

Inhibikase Therapeutics Announces Dosing of First Parkinson's Patient in its Phase 1b Clinical Trial of IkT-148009

Oct 04, 2021 8:05am EDT

Inhibikase Therapeutics Announces Interim Three-month Results from Chronic Toxicology Studies of its Oral c-Abl Kinase Inhibitor, IkT-148009, in Development for Treatment of Parkinson's Disease

Sep 23, 2021 8:05am EDT

Inhibikase Therapeutics Receives Grant from U.S. National Institutes of Health to Evaluate IkT-148009 for the Treatment of Multiple System Atrophy

Sep 07, 2021 8:00am EDT

Inhibikase Therapeutics to Present at Upcoming H.C. Wainwright 23rd Annual Global Investment Conference

Aug 16, 2021 4:45pm EDT

Inhibikase Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Period Activity

Jul 26, 2021 8:42am EDT

Inhibikase Therapeutics Receives FDA Clearance To Begin Evaluation of IkT-148009 in Parkinson's Patients

Jun 18, 2021 6:45pm EDT

Inhibikase Therapeutics Announces Closing of Follow-On Offering of Common Stock

Jun 15, 2021 7:40pm EDT

Inhibikase Therapeutics Prices Follow-On Public Offering of Common Stock

May 25, 2021 8:00am EDT

Inhibikase Therapeutics to Present at Upcoming Jefferies Virtual Healthcare Conference & Others

May 17, 2021 4:05pm EDT

Inhibikase Therapeutics Reports First Quarter 2021 Financial Results and Highlights Recent Period Activity

  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • Next Pagearrow_forward
rss_feed News RSS
  • Visit us on Facebook
  • Visit us on Twitter
  • Visit us on Linkedin
  • Visit us on Youtube
©2025 Inhibikase Therapeutics, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap